多发性骨髓瘤患者单克隆抗体相关肿瘤溶解综合征:基于FAERS数据库的药物警戒研究
本研究基于FAERS数据库2016年Q1至2022年Q4数据,采用不成比例分析、药物相互作用信号及发病时间分析,探讨多发性骨髓瘤患者使用单克隆抗体与肿瘤溶解综合征的关联。共纳入274例TLS报告,达雷妥尤单抗、埃罗妥珠单抗和belantamab mafodotin在排除已知混杂因素后呈现稳健的不成比例信号(IC025>0),且达雷妥尤单抗在所有MM抗癌药物中TLS信号最高。
要点
- 达雷妥尤单抗、埃罗妥珠单抗和belantamab mafodotin与TLS存在稳健不成比例信号(IC025>0)。
- 达雷妥尤单抗在MM抗癌药物中TLS不成比例信号最高。
- 合用升高尿酸、诱发高钾血症或低钙血症的药物可增加TLS报告频率(Ω025>0)。
核心结论
- 上市后药物警戒分析检测到MM患者中单克隆抗体与TLS的报告关联。
- 需设计稳健的流行病学研究验证上述发现。
研究设计与样本
- 基于FAERS数据库2016年Q1至2022年Q4数据的药物警戒研究。
- 采用不成比例分析(IC)评估单克隆抗体与TLS关联,并排除已知混杂因素。
- 采用Ω收缩测量法计算药物相互作用信号,采用参数分布及拟合优度检验分析发病时间。
- 共纳入274例单克隆抗体相关TLS报告。
主要发现
- 274例单克隆抗体相关TLS报告中,27%患者死亡,20.1%发生危及生命的情况。
- 排除已知混杂因素后,达雷妥尤单抗、埃罗妥珠单抗和belantamab mafodotin呈现稳健的不成比例TLS信号(IC025>0)。
- 达雷妥尤单抗在所有MM抗癌药物中TLS不成比例信号最高。
- 达雷妥尤单抗、伊沙妥昔单抗、埃罗妥珠单抗和belantamab mafodotin的TLS报告中位发病时间分别为1.5、14.5、5.5和5.5天。
- 合用已知升高尿酸、诱发高钾血症或低钙血症的药物可提高单克隆抗体相关TLS的报告频率(Ω025>0)。
关键数值与推荐
- 不成比例信号判定标准:IC025>0。
- 药物相互作用信号判定标准:Ω025>0。
- 达雷妥尤单抗、伊沙妥昔单抗、埃罗妥珠单抗和belantamab mafodotin的TLS中位发病时间分别为1.5、14.5、5.5和5.5天。
- 274例单克隆抗体相关TLS报告中27%死亡、20.1%危及生命。
临床怎么用
- 对使用达雷妥尤单抗、埃罗妥珠单抗或belantamab mafodotin的MM患者应警惕TLS发生。
- 达雷妥尤单抗相关TLS中位发病时间为1.5天,提示用药早期需密切监测。
- 应关注合用升高尿酸、诱发高钾血症或低钙血症药物患者的TLS风险。
局限性
- 本研究为基于自发报告数据库的药物警戒分析,需设计稳健的流行病学研究验证发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although some tumor lysis syndrome (TLS) cases have been reported with patients with multiple myeloma (MM) taking monoclonal antibodies (mAbs), the association between TLS and mAbs remains mostly unknown. We aim to investigate the association between TLS and mAbs and describe clinical features. We conducted a disproportionality analysis to investigate the link between mAbs and TLS by excluding known confounders and compared with other anticancer drugs. The association between mAbs and TLS was evaluated using information component (IC). Drug-drug interaction signals were calculated based on the Ω shrinkage measure. Parametric distribution with the goodness-of-fit test was used for the reported time-to-onset analysis. From 2016 Q1, to 2022 Q4, a total of 274 TLS with mAbs were reported in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. There were 27% of patients with TLS with mAbs who died and 20.1% occurred a life-threatening situation. Daratumumab, elotuzumab, and belantamab mafodotin presented a robust disproportionate signal of TLS after excluding known confounders (IC025 > 0). Daratumumab had the highest disproportionate signal of TLS among all anticancer drugs for MM. Reported time-to-onset analysis showed the median days for TLS with daratumumab, isatuximab, elotuzumab, and belantamab mafodotin were 1.5, 14.5, 5.5, and 5.5 days, respectively. The drug-drug interaction analysis showed the co-administration of drugs known to increase urate, induce hyperkalemia, or hypocalcemia elevated the reporting frequency for TLS with mAbs (Ω025 > 0). Our postmarketing pharmacovigilance analysis detected the reporting association of TLS and mAbs in patients with MM. Additional studies with robust epidemiological study designs that can validate these findings are warranted.
引用
- Xia S, Gong H, Zhao Y, et al. Tumor Lysis Syndrome Associated with Monoclonal Antibodies in Patients with Multiple Myeloma: A Pharmacovigilance Study Based on the FAERS Database. Clin Pharmacol Ther. 2023. PMID: 37086211. doi:10.1002/cpt.2920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。